Beta
Trial Radar KI
Die klinische Studie NCT06618911 für Funktionelle Dyspepsie ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht

Evaluation of the Efficacy of Electroacupuncture in the Treatment of Functional Dyspepsia 180

Offene Rekrutierung
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06618911 ist eine interventionsstudie zur Untersuchung von Funktionelle Dyspepsie und hat den Status offene rekrutierung. Die Studie startete am 13. April 2025 und soll 180 Teilnehmer aufnehmen. Durchgeführt von Yi Liang ist der Abschluss für 30. September 2026 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 29. August 2025 aktualisiert.
Kurzbeschreibung

Brief Summary Template for the Study:

The goal of this clinical trial is to evaluate whether electroacupuncture can treat functional dyspepsia (FD) in adult participants aged 18 to 65 years, including both males and females, who have been diagnosed with functional dyspepsia based on the Rome IV criteria. The main questions it aims to answer are:

  • Does 5 Hz electroacupuncture improve symptoms in functional dyspepsi...
Mehr anzeigen
Offizieller Titel

Evaluation of the Efficacy of Electroacupuncture in the Treatment of Functional Dyspepsia: A Pilot Study

Erkrankungen
Funktionelle Dyspepsie
Weitere Studien-IDs
  • 20240903074110247
NCT-Nummer
Studienbeginn (tatsächlich)
2025-04-13
Zuletzt aktualisiert
2025-08-29
Studienende (vorauss.)
2026-09-30
Geplante Rekrutierung
180
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Offene Rekrutierung
Stichwörter
electroacupuncture
functional dyspepsia
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Doppelt verblindet
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Experimentell5 Hz Electroacupuncture Group
Participants will receive electroacupuncture at a frequency of 5 Hz at four acupoints: Liangmen (ST21) and Tianshu (ST25) (local acupoints), and Zusanli (ST36) and Xiajuxu (ST39) (distal acupoints). Disposable needles will be inserted until the "deqi" sensation is achieved. The needles will be connected to an SDZ-IIB electroacupuncture device set at 5 Hz, with stimulation lasting 30 minutes per session. Participants ...Mehr anzeigen
5 Hz electroacupuncture
Intervention Description: The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation. Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and ...Mehr anzeigen
Experimentell100 Hz Electroacupuncture Group
Participants will receive electroacupuncture at a frequency of 100 Hz at the same four acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Needles will be inserted to induce the "deqi" sensation and connected to an SDZ-IIB device set at 100 Hz, with stimulation lasting 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This group assesse...Mehr anzeigen
100 Hz electroacupuncture
Intervention Description: The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation. Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and ...Mehr anzeigen
Schein-VergleichspräparatSham Electroacupuncture (Control) Group
Participants will receive sham electroacupuncture at the same acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Non-penetrating needles will touch the skin but will not induce "deqi." A sham electroacupuncture device (no actual current) will be used, and treatment will last 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This arm se...Mehr anzeigen
Schein-Elektroakupunktur
Participants will receive sham electroacupuncture at the same acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Non-penetrating needles will touch the skin but will not induce \"deqi.\" A sham electroacupuncture device (no actual current) will be used, and treatment will last 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). T...Mehr anzeigen
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Symptom Improvement Rate at Week 4
The primary outcome is the percentage of participants experiencing symptom improvement using the 7-point Likert scale for Overall Treatment Effect (OTE). The Overall Treatment Effect (OTE) questionnaire was categorized as "extremely worse than baseline," "worse than baseline," "slightly worse than baseline," "no change," "slightly improved than baseline," "improved than baseline," or "much improved than baseline." Participants will rate their symptom severity compared to baseline, and those reporting "improved than baseline" or "much improved than baseline"will be considered responders. The primary outcome will assess the efficacy of 5 Hz and 100 Hz electroacupuncture compared to sham treatment.
4 weeks after the start of treatment.
Main Symptom Resolution Rate at Week 4
The second primary outcome is the rate of complete resolution of the main symptoms of functional dyspepsia at week 4. For Postprandial Distress Syndrome (PDS), the primary symptoms are postprandial fullness and early satiety; for Epigastric Pain Syndrome (EPS), the main symptoms are epigastric pain and burning. Complete resolution is defined as a score of 0 for the respective main symptoms on a validated symptom severity scale. The severity of each symptom is divided into: no symptoms (0 points), mild (1 point), moderate (2 points), and severe (3 points). The outcome will compare the resolution rates between the 5 Hz, 100 Hz, and sham electroacupuncture groups.
4 weeks after the start of treatment.
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Global Overall Symptom (GOS) Score Change
The Global Overall Symptom (GOS) score assesses eight symptoms associated with functional dyspepsia (e.g., epigastric pain, burning, fullness, early satiety, nausea, bloating). Scores range from 1 (no problem) to 7 (very severe problem). Scoring is as follows: 1 = no problem (no symptoms); 2 = minimal problem (can be easily ignored); 3 = mild problem (can be ignored with effort); 4 = moderate problem (cannot be ignored, but does not interfere with daily activities); 5 = moderately severe problem (cannot be ignored, occasionally limits daily activities); 6 = severe problem (cannot be ignored, often limits concentration on daily activities); 7 = very severe problem (cannot be ignored, severely limits daily activities. The change from baseline to week 4 will be compared between the 5 Hz, 100 Hz, and sham electroacupuncture groups.
Baseline to Week 4
Nepean Dyspepsia Index (NDI) Score Change
The Nepean Dyspepsia Index (NDI) evaluates the impact of dyspepsia on patients \'quality of life across five domains (e.g., tension, interference with daily activities). The change in NDI score from baseline to week 4 will be used to assess the efficacy of the interventions in improving quality of life. Higher scores on the Nepean Dyspepsia Index (NDI) indicate more severe symptoms
Baseline to Week 4
Hospital Anxiety and Depression Scale (HADS) Score Change
The Hospital Anxiety and Depression Scale (HADS) measures levels of anxiety and depression, which are often associated with functional dyspepsia. Changes in HADS scores from baseline to week 4 will be evaluated to determine if electroacupuncture has an impact on emotional well-being. The scores of anxiety and depression subscales are divided into: 0-7 points for no symptoms; 8-10 points for suspected presence; 11-21 points for definite presence; When scoring, 8 points is the starting point, that is, both suspected and symptomatic are positive.
Baseline to Week 4
Treatment Expectation Score
Participants\' expectations regarding the effectiveness of electroacupuncture will be assessed using a 5-point Likert scale (e.g., strongly agree to strongly disagree) prior to the first treatment. This outcome will be used to determine the role of treatment expectations in the perceived efficacy of electroacupuncture.
Prior to the first treatment (Baseline)
Blind evaluation
Participants perception of whether they received real or sham electroacupuncture will be assessed after the 1st and 6th treatment sessions to evaluate the effectiveness of blinding in the sham group.
immediately after 1st and 6th treatment sessions
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
  • Diagnosed with functional dyspepsia based on Rome IV diagnostic criteria.
  • Aged 18 to 80 years, inclusive, with no gender restrictions.
  • Normal endoscopy results within the past year, showing no structural explanation for symptoms.
  • No acupuncture treatment in the last month.
  • Not participating in any other clinical trials in the past 2 months.
  • Able to understand and provide informed consent.

  • Presence of serious or malignant diseases (e.g., cirrhosis, heart failure, gastrointestinal tumors) that could explain dyspepsia symptoms.
  • Positive for Helicobacter pylori infection based on C-13 urea breath test or gastric biopsy.
  • History of gastrointestinal surgery (excluding laparoscopic and other minimally invasive surgeries).
  • Recent use (within 2 weeks) of medications affecting dyspepsia, including prokinetics, proton pump inhibitors, antacids, or antidepressants.
  • Presence of severe mental or physical conditions, such as dementia or illiteracy, that could interfere with study participation.
  • Severe coagulation disorders.
  • Substance abuse or alcohol dependence.
  • Pregnant or breastfeeding women.
Yi Liang logoYi Liang
Zhejiang Provincial Department of Science and Technology logoZhejiang Provincial Department of Science and Technology
Verantwortliche Partei
Yi Liang, Prüfsponsor, Research Fellow, The Third Affiliated hospital of Zhejiang Chinese Medical University
Zentrale Studienkontakte
Kontakt: Yi Liang, Doctor, +86 571 86633328, [email protected]
4 Studienstandorte in 1 Ländern

None Selected

The Third Affiliated Hospital of Zhejiang Chinese Medicinal University, Hangzhou, None Selected, 310053, China
Chenben Zhang, Kontakt, +86-18815051075, [email protected]
Offene Rekrutierung

Zhejiang

Hangzhou First People's Hospital, Hangzhou, Zhejiang, 310053, China
siyi zheng, Kontakt, +86-15990088547, [email protected]
Offene Rekrutierung
Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310053, China
siyi zheng, Kontakt, +86-15990088547, [email protected]
Offene Rekrutierung
The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China
Xiaojing Wang, Kontakt, +86-19857011126, [email protected]
Offene Rekrutierung